Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ)
CNY 13.93
(-0.5%)
CNY 13.93
(-0.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.18 Billion CNY | -18.65% |
| 2022 | 2.53 Billion CNY | 7.99% |
| 2021 | 2.44 Billion CNY | 114.82% |
| 2020 | 1.07 Billion CNY | 24.19% |
| 2019 | 856.18 Million CNY | 1.92% |
| 2018 | 813.63 Million CNY | 19.27% |
| 2017 | 677.35 Million CNY | 35.16% |
| 2016 | 513.4 Million CNY | 8.16% |
| 2015 | 461.9 Million CNY | 15.97% |
| 2014 | 390.8 Million CNY | 39.65% |
| 2013 | 298.56 Million CNY | 29.73% |
| 2012 | 239.17 Million CNY | 29.73% |
| 2011 | 187.11 Million CNY | 43.82% |
| 2010 | 132.68 Million CNY | 12.21% |
| 2009 | 118.24 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 65.4 Million CNY | -85.26% |
| 2024 Q1 | 373.47 Million CNY | 9.6% |
| 2024 Q2 | 404.86 Million CNY | 13.35% |
| 2023 Q4 | 342.71 Million CNY | 25.93% |
| 2023 Q1 | 367.29 Million CNY | -46.48% |
| 2023 Q2 | 340.56 Million CNY | -7.28% |
| 2023 FY | - CNY | -18.65% |
| 2023 Q3 | 272.14 Million CNY | -20.09% |
| 2022 Q1 | 259.88 Million CNY | -25.6% |
| 2022 FY | - CNY | 7.99% |
| 2022 Q4 | 686.21 Million CNY | 75.65% |
| 2022 Q3 | 390.68 Million CNY | 20.18% |
| 2022 Q2 | 325.09 Million CNY | 25.09% |
| 2021 FY | - CNY | 114.82% |
| 2021 Q4 | 349.32 Million CNY | 6.12% |
| 2021 Q3 | 329.18 Million CNY | -8.39% |
| 2021 Q2 | 359.31 Million CNY | 5.68% |
| 2021 Q1 | 340 Million CNY | 43.43% |
| 2020 Q3 | 270.75 Million CNY | -8.06% |
| 2020 FY | - CNY | 24.19% |
| 2020 Q1 | 265.66 Million CNY | 29.44% |
| 2020 Q2 | 294.47 Million CNY | 10.84% |
| 2020 Q4 | 237.05 Million CNY | -12.44% |
| 2019 Q4 | 205.24 Million CNY | -1.29% |
| 2019 FY | - CNY | 1.92% |
| 2019 Q3 | 207.93 Million CNY | 2.09% |
| 2019 Q2 | 203.68 Million CNY | -12.9% |
| 2019 Q1 | 233.85 Million CNY | 12.92% |
| 2018 Q2 | 217.16 Million CNY | -0.25% |
| 2018 Q1 | 217.71 Million CNY | 13.01% |
| 2018 FY | - CNY | 19.27% |
| 2018 Q4 | 207.09 Million CNY | 8.77% |
| 2018 Q3 | 190.4 Million CNY | -12.32% |
| 2017 Q2 | 145.9 Million CNY | -10.47% |
| 2017 Q1 | 162.97 Million CNY | 34.52% |
| 2017 FY | - CNY | 35.16% |
| 2017 Q4 | 192.65 Million CNY | 25.9% |
| 2017 Q3 | 153.02 Million CNY | 4.88% |
| 2016 Q1 | 103.27 Million CNY | 17.98% |
| 2016 Q2 | 135.35 Million CNY | 31.06% |
| 2016 FY | - CNY | 8.16% |
| 2016 Q3 | 136.18 Million CNY | 0.61% |
| 2016 Q4 | 121.14 Million CNY | -11.04% |
| 2015 Q4 | 87.53 Million CNY | -25.11% |
| 2015 FY | - CNY | 15.97% |
| 2015 Q2 | 90.04 Million CNY | -38.03% |
| 2015 Q1 | 145.3 Million CNY | 118.16% |
| 2015 Q3 | 116.88 Million CNY | 29.8% |
| 2014 Q2 | -855.41 Million CNY | -182.34% |
| 2014 FY | - CNY | 39.65% |
| 2014 Q4 | 66.6 Million CNY | -41.53% |
| 2014 Q3 | 113.9 Million CNY | 113.32% |
| 2014 Q1 | 1.03 Billion CNY | 1187.96% |
| 2013 Q4 | 80.66 Million CNY | 17.85% |
| 2013 FY | - CNY | 29.73% |
| 2013 Q2 | -652.92 Million CNY | -182.25% |
| 2013 Q3 | 68.44 Million CNY | 110.48% |
| 2013 Q1 | 793.8 Million CNY | 0.0% |
| 2012 FY | - CNY | 29.73% |
| 2011 FY | - CNY | 43.82% |
| 2010 FY | - CNY | 12.21% |
| 2009 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cachet Pharmaceutical Co., Ltd. | 912.84 Million CNY | -139.045% |
| ZJAMP Group Co., Ltd. | 1.51 Billion CNY | -44.033% |
| Luyan Pharma Co.,Ltd. | 819.73 Million CNY | -166.198% |
| Ji Yao Holding Group Co., Ltd. | -225.02 Million CNY | 1069.716% |